Promising Psoriasis Treatment Advances to Clinical Trial Stage

    Lipidor’s recent approval from the Indian drug regulatory authority (DCGI) to initiate a clinical Phase III trial with the drug candidate AKP02G2 for the treatment of psoriasis is a promising advancement in the field of dermatological research. Psoriasis, a chronic autoimmune condition characterized by patches of abnormal skin, presents significant challenges for patients. By comparing AKP02G2 with the market-leading product Enstilar, this study aims to assess the drug’s therapeutic effect in individuals with mild to moderate psoriasis. 

    The anticipated results of this Phase III trial hold the potential to not only enhance treatment options but also pave the way for market approval in Europe, offering hope for improved outcomes and quality of life for psoriasis patients. 

    Key points:

    • Lipidor has obtained approval from DCGI to commence a clinical Phase III trial with AKP02G2 for psoriasis treatment.
    • The study will compare AKP02G2 with Enstilar to evaluate its therapeutic effect in patients with mild to moderate psoriasis.
    • The Phase III trial will involve 294 patients and will be conducted by Cliantha Research, an experienced CRO in dermatological research.
    • The clinical trial material will be manufactured by Oy Medfiles Ltd in Finland.
    • Lipidor has entered into a licensing agreement with RELIFE S.r.l. in Italy for exclusive rights to register, market, and sell AKP02G2 in Europe, the CIS countries, the Asia-Pacific region, and Turkey following a successful study.
    • Continued funding is required for the study to proceed as planned.
    • The goal is to have the study results available by early 2025.
    • Stock ticker symbol: LIPI
    • Stock exchange: First North Stockholm


    For further information, click here.

    David Zingmark
    I'm a passionate individual dedicated to shining a spotlight on incredible companies. My goal is is to uncover stories by telling the most complex operations into simplified words, empowering you as a reader to gain better insights and make informed investment and/or business choices.

    Don't miss this

    Fear of missing out?